Logo image of RGLS

REGULUS THERAPEUTICS INC (RGLS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RGLS - US75915K3095 - Common Stock

8.16 USD
+0.02 (+0.25%)
Last: 6/24/2025, 8:00:02 PM
8.02 USD
-0.14 (-1.72%)
After Hours: 6/24/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RGLS. RGLS was compared to 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability. RGLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RGLS has reported negative net income.
RGLS had a negative operating cash flow in the past year.
In the past 5 years RGLS always reported negative net income.
In the past 5 years RGLS always reported negative operating cash flow.
RGLS Yearly Net Income VS EBIT VS OCF VS FCFRGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

RGLS has a worse Return On Assets (-63.51%) than 61.22% of its industry peers.
With a Return On Equity value of -68.85%, RGLS perfoms like the industry average, outperforming 55.83% of the companies in the same industry.
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROIC N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
RGLS Yearly ROA, ROE, ROICRGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGLS Yearly Profit, Operating, Gross MarginsRGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RGLS has been increased compared to 1 year ago.
The number of shares outstanding for RGLS has been increased compared to 5 years ago.
There is no outstanding debt for RGLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGLS Yearly Shares OutstandingRGLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RGLS Yearly Total Debt VS Total AssetsRGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 46.61 indicates that RGLS is not in any danger for bankruptcy at the moment.
RGLS has a Altman-Z score of 46.61. This is amongst the best in the industry. RGLS outperforms 98.03% of its industry peers.
RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.61
ROIC/WACCN/A
WACCN/A
RGLS Yearly LT Debt VS Equity VS FCFRGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RGLS has a Current Ratio of 16.31. This indicates that RGLS is financially healthy and has no problem in meeting its short term obligations.
RGLS has a better Current ratio (16.31) than 89.59% of its industry peers.
A Quick Ratio of 16.31 indicates that RGLS has no problem at all paying its short term obligations.
The Quick ratio of RGLS (16.31) is better than 89.59% of its industry peers.
Industry RankSector Rank
Current Ratio 16.31
Quick Ratio 16.31
RGLS Yearly Current Assets VS Current LiabilitesRGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RGLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RGLS Yearly Revenue VS EstimatesRGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
RGLS Yearly EPS VS EstimatesRGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RGLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RGLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGLS Price Earnings VS Forward Price EarningsRGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGLS Per share dataRGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as RGLS's earnings are expected to grow with 22.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y22.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (6/24/2025, 8:00:02 PM)

After market: 8.02 -0.14 (-1.72%)

8.16

+0.02 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners82.87%
Inst Owner Change-45.35%
Ins Owners2.8%
Ins Owner Change-10.31%
Market Cap564.92M
Revenue(TTM)N/A
Net Income(TTM)-47.52M
Analysts73.33
Price Target8.67 (6.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.3%
Min EPS beat(2)6.63%
Max EPS beat(2)39.98%
EPS beat(4)2
Avg EPS beat(4)2.97%
Min EPS beat(4)-21.11%
Max EPS beat(4)39.98%
EPS beat(8)5
Avg EPS beat(8)-0.32%
EPS beat(12)7
Avg EPS beat(12)2.1%
EPS beat(16)9
Avg EPS beat(16)0.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-27.97%
EPS NQ rev (1m)1.85%
EPS NQ rev (3m)12.4%
EPS NY rev (1m)23.3%
EPS NY rev (3m)11.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.18
P/tB 8.19
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.31
Quick Ratio 16.31
Altman-Z 46.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)221.31%
Cap/Depr(5y)143.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.74%
OCF growth 3YN/A
OCF growth 5YN/A

REGULUS THERAPEUTICS INC / RGLS FAQ

Can you provide the ChartMill fundamental rating for REGULUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to RGLS.


What is the valuation status of REGULUS THERAPEUTICS INC (RGLS) stock?

ChartMill assigns a valuation rating of 1 / 10 to REGULUS THERAPEUTICS INC (RGLS). This can be considered as Overvalued.


How profitable is REGULUS THERAPEUTICS INC (RGLS) stock?

REGULUS THERAPEUTICS INC (RGLS) has a profitability rating of 0 / 10.